Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change
The analysis reveals quality of life and symptom severity in patients with multiple myeloma treated with belamaf-based regimens, suggesting a comparable overall benefit.
Key Points
To evaluate patient-reported outcomes in patients with relapsed/refractory multiple myeloma from DREAMM-7 and DREAMM-8.
Utilized EQ-5D-3L visual analogue scale (VAS), Patient Global Impression of Severity (PGIS), and Patient Global Impression of Change (PGIC) for assessments
Administered PRO measures at baseline, during treatment, and during follow-up
Conducted descriptive statistics and estimated hazard ratios with Cox model
Overall quality of life did not differ between treatment arms in either DREAMM-7 or DREAMM-8
Patients reported lower symptom severity in belamaf arms versus comparators
Median time to first improvement in symptoms was shorter in BELAMAF combinations compared to standard treatments.